Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Cytogenetics

Lung Cancer Panel 8 EGFR BRAF ALK ROS MET PDL1

The Lung Cancer Panel 8 test identifies specific genetic mutations (EGFR, BRAF, ALK, ROS1, MET, PD-L1) in lung cancer tissue. This helps guide personalized treatment decisions for better outcomes. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
Results
Confirm turnaround time with the laboratory before booking.
Preparation
No specific patient preparation is required. The sample is typically obtained during a biopsy or surgery.
Test priceKSh 90,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Lung Cancer Panel 8 EGFR BRAF ALK ROS MET PDL1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of non-small cell lung cancer
  • ✓Guiding treatment decisions for lung cancer
  • ✓Identifying eligibility for targeted therapies
  • ✓Assessing suitability for immunotherapy
  • ✓Monitoring treatment response (in specific contexts)
  • ✓Prognostic information for lung cancer
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in lung cancer tissue that can predict response to targeted therapies and immunotherapies, guiding personalized treatment decisions.
The Lung Cancer Panel 8 test is a comprehensive diagnostic tool used to identify specific genetic mutations in lung cancer tissue. Understanding these mutations is crucial for oncologists to tailor personalized treatment strategies, potentially improving patient outcomes and survival rates. This test looks for changes in several key genes associated with lung cancer growth and response to therapy. Identifying these mutations helps determine the most effective treatment options, including targeted therapies or immunotherapies. This test is recommended for individuals diagnosed with lung cancer, particularly non-small cell lung cancer, to guide treatment decisions. Your healthcare provider will interpret the results in the context of your overall health and cancer diagnosis.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. The sample is typically obtained during a biopsy or surgery.
SampleTumor tissue sample (biopsy or surgical resection). Confirm specific requirements with the laboratory before booking.
MethodologyMolecular testing techniques, such as Next Generation Sequencing (NGS) or Polymerase Chain Reaction (PCR), are used to detect mutations in the specified genes. Confirm the specific methodology with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific genes and may not detect all possible mutations relevant to lung cancer. Results must be interpreted by a qualified healthcare professional in the context of the patient's clinical picture. The test requires adequate tumor tissue for analysis.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test looks for specific genetic mutations in the EGFR, BRAF, ALK, ROS1, MET, and PD-L1 genes within a lung cancer tissue sample.
Identifying these mutations helps doctors choose the most effective treatments, such as targeted therapies or immunotherapies, tailored to the specific characteristics of the cancer.
A sample of the tumor tissue, usually obtained from a biopsy or surgery, is required for this test.
Your doctor will use the results to guide your treatment plan. They will discuss the findings and their implications with you.
No specific preparation is needed from the patient, as the test is performed on a tissue sample.
Confirm the turnaround time with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Catecholamines Plasma Test

Measures epinephrine and norepinephrine levels in plasma to help detect hormonal imbalances related to conditions like hypertension and anxiety. Confirm with the laboratory before booking.

Learn more →

Epstein-Barr Virus Early RNA EBERISH In Situ Hybridization Test

Detects Epstein-Barr Virus (EBV) RNA in tumor tissue to aid in the early diagnosis of EBV-related cancers like lymphomas and nasopharyngeal carcinoma.

Learn more →

CA Cyfra 211 Lung Cancer Marker Test

The CA Cyfra 21-1 Lung Cancer Marker Test measures a specific protein fragment in the blood that can be elevated in lung cancer. It aids in diagnosis and monitoring.

Learn more →

Breast Cancer ER PR HER2 Ki67

The Breast Cancer ER PR HER2 Ki67 test analyzes key markers in breast tumor tissue to guide personalized treatment decisions. It measures hormone receptors (ER, PR), HER2 protein, and the Ki-67 proliferation marker.

Learn more →
Chat on WhatsApp